ClinicalTrials.gg
RecruitingNCT05100420HiRO-HCMUpdated Oct 9, 2026

Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository

An observational study in Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy and Familial Hypertrophic Cardiomyopathy, sponsored by Montreal Heart Institute. Recruiting at 17 sites in Canada. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Montreal Heart Institute · Observational

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 8 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
2,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Cardiomyopathy, Hypertrophic with a site in Canada — 5 open to participants now, 11 under way, 4 of them phase 3. Cardiomyopathy, Hypertrophic · Canada.

Planned enrollment
5th of 13
2,000 · median 544
Started
2021
with 2 others
Observational
13 of 26
3 open now
Primary completion
2030-12
later than 9 of 10 live
Registered
16th of 26
by date

Among the 26 studies in Cardiomyopathy, Hypertrophic with a site in Canada, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2021, is one of 13 observational ones, reaches primary completion later than 9 of the 10 other live ones, and was the 16th registered.

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

5 of the 26 studies in Cardiomyopathy, Hypertrophic with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Cardiomyopathy, Hypertrophic with a site in Canada, or all of them as a file.
02

Study summary

The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD). The HiRO Hypertrophic Cardiomyopathy registry, biobank and imaging data repository (HiRO-HCM) is a multicenter study that will prospectively enroll patients with HCM as well as those carrying sarcomeric gene variants predisposing to HCM.

The objectives of HiRO-HCM are:

  1. to better understand the natural history of the disease and identify clinical markers and biomarkers for adverse outcomes;
  2. to derive and validate risk prediction models for disease expression, complications and response to therapy;
  3. to better define the genetic architecture of sarcomeric and non-sarcomeric HCM.
Read the detailed description

PATIENT ENROLLMENT:

Eligible patients will be included from HiRO sites or collaborating centres. Patients will be contacted by the local investigator or a research coordinator. Willing individuals will be interviewed by the research coordinator and given information about HiRO-HCM. The consent form will be reviewed and discussed with the coordinator. The investigators will also be available for any questions that the coordinator is unable to answer. Potential participants will have sufficient time to consider participating in HiRO-HCM. Written informed consent will be obtained from eligible patients or legal guardians. Participants will be able to withdraw their participation at any time.

BASELINE DATA COLLECTION:

Clinical data will be collected from willing/consented registry participants. All demographic and medical information pertaining to the cardiac history and comorbidities of eligible patients will be collected at baseline, including clinical information, diagnostic test results, genetic testing results, family history and ethnicity, as well as current and previous treatments. Healthcare information will be coded in compliance with Canada's Tri-Council Policy Statement criteria: direct identifiers will be removed and replaced with a unique study code that does not use personal information such as the participant's health number, social insurance number or name. The coded data will be transferred into the clinical research database using a web-based electronic case report form (eCRF), using REDcap. The clinical research database will be managed by the Montreal Health Innovations Coordinating Center (MHICC; mhicc.org). Study participants will be identified by subject number only (research HiRO-HCM ID). The research ID uniquely identifying each subject eCRF within the database will be attributed in REDcap but the master list of registry participants with their study identifiers will be kept separately from the clinical research database. This master list will be stored in an encrypted file within the research office of each site investigators under their supervision. Only the site investigators and their local research staff will have access to this list.

BIOSPECIMEN COLLECTION:

Consented participants will undergo biosampling at enrollment for the primary purpose of DNA isolation and genetic studies. The preferred biosampling method is blood sampling using a standard venipuncture. Blood sampling allows for high quality DNA extraction as well as collection of plasma for future circulating biomarkers studies. As an alternative to blood sampling, collection of saliva using DNA genotek kits, or equivalent, is allowed in the following contexts:

  • Patient enrollment is performed remotely. This is particularly relevant in the context of the ongoing SARS-CoV-2 pandemic, where physical distancing is preferred.
  • Patient is a child \<14 years old without planned clinically indicated blood sampling.

Participants for which saliva collection is chosen should be made aware of the possibility to request a blood sample in the future.

The HiRO-HCM biobank will be directed by the Beaulieu-Saucier Pharmacogenomics Center (PGx; http://www.pharmacogenomics.ca), operating under Good Laboratory/Clinical Practices (GLP/GCP) standards.

DNA isolation and long-term storage will be done at PGx, while long-term storage of plasma samples will be done at the MHI research center, in dedicated freezers located in a room with restricted access. Samples of subjects that withdraw their participation will be destroyed.

IMAGING DATA TRANSFER:

For all consented participants, de-identified transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR) imaging data will be transferred to the Montreal Heart Institute imaging core-lab for central interpretation and long term storage. At minimum, the following imaging studies are requested:

  1. First available TTE
  2. First available CMR, preferably with gadolinium injection
  3. Last available TTE
  4. Last available CMR, preferably with gadolinium injection

For patients that underwent alcohol septal ablation, surgical myectomy and/or cardiac transplantation, the last available TTE and CMR studies prior to all these interventions should also be transferred.

Digital Imaging and Communications in Medicine (DICOM) imaging data will be de-identified prior to transfer. De-identification will be performed at each site, by removing the patient's name and replacing the clinical identification number with the research HiRO-HCM ID. DICOM data will be stored using the Canadian Imaging network infrastructure (canadianimagingnetwork.org).

PATIENT FOLLOW-UP:

Participants with a clinical diagnosis of HCM are expected to undergo yearly clinic visits, as per standard care. Participants without yearly clinic visits will be contacted by phone. Follow-up visits will assess for living status, functional class, as well as for arrhythmic, heart failure and thromboembolic events. Follow-up data will be entered by the local investigator and/or research coordinator into an eCRF managed by the MHICC. De-identified documentation of clinical events including ECG, intracardiac tracing, clinical notes, imaging reports, and procedural reports will be uploaded to the database for centralized ad-hoc event adjudication.

De-identified DICOM images of TTE and CMR studies performed clinically during follow-up will be uploaded to the MHI imaging core-lab similarly as for baseline imaging studies.

For participants that will undergo septal myectomy for drug-refractory obstructive HCM, or cardiac transplantation, surgical tissue samples will be collected using the Qiagen PAXgene tissue preservation system or equivalent, allowing for future somatic DNA, RNA and proteomic analyses. The samples will be stored at the MHI research center.

03

Conditions studied

  • Hypertrophic Cardiomyopathy
  • Hypertrophic Obstructive Cardiomyopathy
  • Familial Hypertrophic Cardiomyopathy
  • Cardiomyopathies

Keywords

  • Genetics
  • Echocardiography
  • Cardiac magnetic resonance imaging
  • Biomarker
  • Sudden cardiac death
  • Genome-wide association study
  • Risk prediction model
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The HiRO-HCM registry, biobank and imaging data repository is a multicenter collaboration that will prospectively enroll patients with HCM as well as those carrying genetic variants predisposing to HCM.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with (1) AND/OR (2)

  1. Clinical diagnosis of HCM, defined as

    1. maximal LVWT ≥15mm, or
    2. maximal LVWT ≥13mm, in presence of a diagnosis of first degree relative with HCM, or
    3. septal wall thickness with z-score >2 in a child

    AND/OR

  2. Carrier of a pathogenic or likely pathogenic genetic variant in a sarcomeric gene (ACTC1, FHOD3, MYBPC3, MYH7, MYL2, MYL3, TNNI3, TNNT2, TPM1). Variant classification should be performed by a certified diagnostic laboratory according to the American College of Medical Genetics and Genomics (ACMG) guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Clinical or molecular diagnosis of Noonan syndrome or other Rasopathies
  2. Clinical or molecular diagnosis of metabolic disease associated with cardiomyopathy, such as Pompe (GAA), Fabry (GLA), Danon (LAMP2), AMP-kinase (PRKAG2), and carnitine disorders
  3. Clinical diagnosis of a neuromuscular disease associated with cardiomyopathy, such as Friedrich's ataxia
  4. Clinical diagnosis of cardiac amyloidosis with or without the presence of genetic variants in TTR
  5. Clinical or molecular diagnosis of mitochondrial cardiomyopathy
  6. Diagnosis of HCM >65 years old AND absence of pathogenic or likely pathogenic variant in a sarcomeric gene (as defined in inclusion criterion 1B above)
  7. History of myocardial infarction
  8. History of moderate or severe aortic stenosis
  9. History of congenital heart defects requiring percutaneous or surgical correction
  10. History of severe hypertension defined as a systolic blood pressure >180 mmHg and/or diastolic blood pressure >110 mmHg AND absence of pathogenic or likely pathogenic variant in a sarcomeric gene (as defined in inclusion criterion 1B above)
  11. Refusal to provide or to provide a biospecimen for DNA analysis
  12. No possibility to upload transthoracic echocardiogram or cardiac magnetic resonance imaging for core lab interpretation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Create a Canadian Research Database, a biobank and an imaging data repository for those affected by hypertrophic cardiomyopathy (HCM) or carrying a sarcomeric gene variant associated with HCM

    Time frame: 5 years

07

Study locations

15 of 17 sites recruiting
  • Mazankowski Alberta Heart Institute
    Edmonton, Alberta, Canada
    Recruiting
    • Gavin Oudit · Principal investigator
  • UBC St. Paul's Hospital
    Vancouver, British Columbia, Canada
    Recruiting
    • Zachary Laksman · Sub investigator
    • Thomas Roston · Principal investigator
    • Kevin Ong · Sub investigator
  • Vancouver Island Health Authority
    Victoria, British Columbia, Canada
    Recruiting
    • Martin van Zyl · Principal investigator
  • St. Boniface Hospital
    Winnipeg, Manitoba, Canada
    Recruiting
    • Colette Seifer, MD · Principal investigator
  • IWK Health Centre
    Halifax, Nova Scotia, Canada
    Recruiting
    • Santokh Dhillon · Principal investigator
  • Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia, Canada
    Recruiting
    • David Lee · Principal investigator
  • McMaster University
    Hamilton, Ontario, Canada
    Recruiting
    • Jason D Roberts · Principal investigator
  • Kingston Health Sciences Centre
    Kingston, Ontario, Canada
    Not yet recruiting
    • Amer Johri, MD · Principal investigator
  • London Health Sciences Centre
    London, Ontario, Canada
    Recruiting
    • Habib Khan · Principal investigator
  • University of Ottawa Heart Institute
    Ottawa, Ontario, Canada
    Recruiting
    • Thi Kim Hanh Nguyen · Principal investigator
  • Hôpital du Sacré-Cœur-de-Montréal
    Montreal, Quebec H4J 1C5, Canada
    Recruiting
  • Centre Hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec, Canada
    Recruiting
    • François Tournoux · Principal investigator
  • Hôpital Ste-Justine
    Montreal, Quebec, Canada
    Recruiting
    • Anne Fournier · Principal investigator
  • McGill University Health Centre
    Montreal, Quebec, Canada
    Recruiting
    • Jacqueline Joza · Principal investigator
  • Montreal Heart Institute
    Montreal, Quebec, Canada
    Recruiting
    • Rafik Tadros · Principal investigator
    • Patrick Garceau · Sub investigator
    • Philippe L'Allier · Sub investigator
    • Maxime Tremblay-Gravel · Sub investigator
    • Julia Cadrin-Tourigny · Sub investigator
    • Geneviève Giraldeau · Sub investigator
    • Lena Rivard · Sub investigator
    • Jacinthe Boulet · Sub investigator
    • Adrian Petzl · Sub investigator
  • Institut Universitaire de Cardiologie et Pneumologie de Québec
    Québec, Quebec, Canada
    Recruiting
    • Christian Steinberg · Principal investigator
  • Jim Pattison Children's Hospital and Royal University Hospital
    Saskatoon, Saskatchewan, Canada
    Not yet recruiting
    • Brandon Chalazan, MD PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2030, 118 months after the start.

Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 118 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Feb 2026 → Dec 2030 and completion Aug 2027 → Dec 2035.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2021
First posted
Oct 29, 2021
StartActual
Feb 23, 2021
Primary completionEst.
Dec 31, 2030was Feb 2026
CompletionEst.
Dec 31, 2035was Aug 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Recruiting
changed Oct 9, 2026
Sites
4 sites added. 13 sites changed recruiting status (13 now recruiting)
Show 13 sites
  • Mazankowski Alberta Heart Institute · Edmonton, Canadano status→Recruiting
  • UBC St. Paul's Hospital · Vancouver, Canadano status→Recruiting
  • Vancouver Island Health Authority · Victoria, Canadano status→Recruiting
  • IWK Health Centre · Halifax, Canadano status→Recruiting
  • Queen Elizabeth II Health Sciences Centre · Halifax, Canadano status→Recruiting
  • McMaster University · Hamilton, Canadano status→Recruiting
  • London Health Sciences Centre · London, Canadano status→Recruiting
  • University of Ottawa Heart Institute · Ottawa, Canadano status→Recruiting
  • Centre Hospitalier de l'Université de Montréal (CHUM) · Montreal, Canadano status→Recruiting
  • Hôpital Ste-Justine · Montreal, Canadano status→Recruiting
  • McGill University Health Centre · Montreal, Canadano status→Recruiting
  • Montreal Heart Institute · Montreal, Canadano status→Recruiting
  • Institut Universitaire de Cardiologie et Pneumologie de Québec · Québec, Canadano status→Recruiting
Show 4 added (4 Canada)
  • St. Boniface Hospital · Winnipeg, Canada
  • Kingston Health Sciences Centre · Kingston, Canada
  • Hôpital du Sacré-Cœur-de-Montréal · Montreal, Canada
  • Jim Pattison Children's Hospital and Royal University Hospital · Saskatoon, Canada
Oct 9, 2026
Primary completion
Feb 23, 2026→Dec 31, 2030
Oct 9, 2026
Study completion
Aug 23, 2027→Dec 31, 2035
Oct 9, 2026
Contact
Study contact now listed: added h•••@icm-mhi.org · •••3330; added c•••@icm-mhi.org · •••3330. See the current contact
Oct 9, 2026
Site contacts
Changed at 13 sites. See the sites
Show 13 sites
  • Mazankowski Alberta Heart Institute · Edmonton, CanadaContact added (no phone or email listed)
  • UBC St. Paul's Hospital · Vancouver, CanadaContact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
  • Vancouver Island Health Authority · Victoria, CanadaContact added (no phone or email listed)
  • IWK Health Centre · Halifax, CanadaContact added (no phone or email listed)
  • Queen Elizabeth II Health Sciences Centre · Halifax, CanadaContact added (no phone or email listed)
  • McMaster University · Hamilton, CanadaContact added (no phone or email listed)
  • London Health Sciences Centre · London, CanadaContact added (no phone or email listed)
  • University of Ottawa Heart Institute · Ottawa, CanadaContact added (no phone or email listed)
  • Centre Hospitalier de l'Université de Montréal (CHUM) · Montreal, CanadaContact added (no phone or email listed)
  • Hôpital Ste-Justine · Montreal, CanadaContact added (no phone or email listed)
  • McGill University Health Centre · Montreal, CanadaContact added (no phone or email listed)
  • Montreal Heart Institute · Montreal, CanadaContact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
  • Institut Universitaire de Cardiologie et Pneumologie de Québec · Québec, CanadaContact added (no phone or email listed)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Enrolling by invitation→Recruiting
    4 sites added. 13 sites changed recruiting status (13 now recruiting)
    Show 13 sites
    • Mazankowski Alberta Heart Institute · Edmonton, Canadano status→Recruiting
    • UBC St. Paul's Hospital · Vancouver, Canadano status→Recruiting
    • Vancouver Island Health Authority · Victoria, Canadano status→Recruiting
    • IWK Health Centre · Halifax, Canadano status→Recruiting
    • Queen Elizabeth II Health Sciences Centre · Halifax, Canadano status→Recruiting
    • McMaster University · Hamilton, Canadano status→Recruiting
    • London Health Sciences Centre · London, Canadano status→Recruiting
    • University of Ottawa Heart Institute · Ottawa, Canadano status→Recruiting
    • Centre Hospitalier de l'Université de Montréal (CHUM) · Montreal, Canadano status→Recruiting
    • Hôpital Ste-Justine · Montreal, Canadano status→Recruiting
    • McGill University Health Centre · Montreal, Canadano status→Recruiting
    • Montreal Heart Institute · Montreal, Canadano status→Recruiting
    • Institut Universitaire de Cardiologie et Pneumologie de Québec · Québec, Canadano status→Recruiting
    Show 4 added (4 Canada)
    • St. Boniface Hospital · Winnipeg, Canada
    • Kingston Health Sciences Centre · Kingston, Canada
    • Hôpital du Sacré-Cœur-de-Montréal · Montreal, Canada
    • Jim Pattison Children's Hospital and Royal University Hospital · Saskatoon, Canada
    Primary completion Feb 23, 2026→Dec 31, 2030
    Study completion Aug 23, 2027→Dec 31, 2035
    Contact Study contact now listed: added h•••@icm-mhi.org · •••3330; added c•••@icm-mhi.org · •••3330. See the current contact
    Site contacts Changed at 13 sites. See the sites
    Show 13 sites
    • Mazankowski Alberta Heart Institute · Edmonton, CanadaContact added (no phone or email listed)
    • UBC St. Paul's Hospital · Vancouver, CanadaContact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
    • Vancouver Island Health Authority · Victoria, CanadaContact added (no phone or email listed)
    • IWK Health Centre · Halifax, CanadaContact added (no phone or email listed)
    • Queen Elizabeth II Health Sciences Centre · Halifax, CanadaContact added (no phone or email listed)
    • McMaster University · Hamilton, CanadaContact added (no phone or email listed)
    • London Health Sciences Centre · London, CanadaContact added (no phone or email listed)
    • University of Ottawa Heart Institute · Ottawa, CanadaContact added (no phone or email listed)
    • Centre Hospitalier de l'Université de Montréal (CHUM) · Montreal, CanadaContact added (no phone or email listed)
    • Hôpital Ste-Justine · Montreal, CanadaContact added (no phone or email listed)
    • McGill University Health Centre · Montreal, CanadaContact added (no phone or email listed)
    • Montreal Heart Institute · Montreal, CanadaContact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
    • Institut Universitaire de Cardiologie et Pneumologie de Québec · Québec, CanadaContact added (no phone or email listed)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05100420
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Rafik Tadros (Cardiologist, Clinician Scientist, Montreal Heart Institute) — Principal investigator
First posted
Oct 29, 2021
Start date
Feb 23, 2021
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Oct 9, 2026

Study contacts

Svenja Koslowski
Contact
hiro-hcm@icm-mhi.org
514-376-3330 ext. 5029
Caroline Girard
Contact
caroline.girard@icm-mhi.org
514-376-3330 ext. 4058
Rafik Tadros, Dr.
principal investigator · Montreal Heart Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion